FindTrial
Sign In

Skin reactions in cancer patients treated with Imatinib (a drug for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor)

Imatinib induced skin reactions in cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/08/035586
Enrollment
60
Registered
2021-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive

Interventions

None listed

Sponsors

Manipal college of Pharmaceutical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In-patients and out-patients visiting the Department of Medical Oncology, KMC, Manipal.

Exclusion criteria

Exclusion criteria: Patients less than 18 years

Design outcomes

Primary

MeasureTime frame
Assessing drug induced skin reactionsTimepoint: 3-4 months from the date of administration—

Secondary

MeasureTime frame
Incidence of Imatinib associated dermatological reactions.Timepoint: 3-4 months from the date of administration—

Countries

India

Contacts

Public ContactNayonika Mukherjee

Kasturba Medical College, MAHE

Ananth.pai@manipal.edu9880239139

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026